RIVAROXABAN
ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
NORTHSTAR RX LL
Indication
Prevention of thromboembolism in paroxysmal atrial fibrillation
Prevention of thromboembolism in paroxysmal atrial fibrillation refers to prophylactic therapy aimed at reducing the risk of ischemic stroke and systemic arterial embolism in individuals with intermittent, self-terminating atrial fibrillation. Read more about Prevention of thromboembolism in paroxysmal atrial fibrillation
20 drugs 18 manufacturers
Drugs that treat it
Common Prevention of thromboembolism in paroxysmal atrial fibrillation therapies.
RIVAROXABAN
ORAL ANTICOAGULANTS·MYOCARDIAL INFARCTION PREVENTION·+10
NOVADOZ PHARMAC
Filter & compare in the drug finder →Opens the drug finder with Prevention of thromboembolism in paroxysmal atrial fibrillation preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPrevention of thromboembolism in paroxysmal atrial fibrillation refers to prophylactic therapy aimed at reducing the risk of ischemic stroke and systemic arterial embolism in individuals with intermittent, self-terminating atrial fibrillation.
In this cardiovascular condition, recurrent episodes of rapid and disorganized atrial activation impair effective mechanical contractility, causing blood stasis particularly within the left atrial appendage.
This stasis promotes intracardiac thrombus formation, which can dislodge and occlude cerebral or systemic vasculature despite episodes spontaneously resolving within seven days.
Clinical risk stratification guides prophylaxis, as the risk of thromboembolic events in paroxysmal disease remains comparable to that of sustained atrial fibrillation.
- nih.gov
Prevention of thromboembolism in paroxysmal atrial fibrillation refers to prophylactic therapy aimed at reducing the risk of ischemic stroke and systemic arterial embolism in individuals with intermittent, self-terminating atrial fibrillation In this cardiovascular condition, recurrent episodes of rapid and disorganized atrial activation impair effective mechanical contractility, causing blood stasis particularly within the left atrial appendage
- nih.gov
Prevention of thromboembolism in paroxysmal atrial fibrillation refers to prophylactic therapy aimed at reducing the risk of ischemic stroke and systemic arterial embolism in individuals with intermittent, self-terminating atrial fibrillation In this cardiovascular condition, recurrent episodes of rapid and disorganized atrial activation impair effective mechanical contractility, causing blood stasis particularly within the left atrial appendage This stasis promotes intracardiac thrombus formati...
- thrombosiscanada.ca
In this cardiovascular condition, recurrent episodes of rapid and disorganized atrial activation impair effective mechanical contractility, causing blood stasis particularly within the left atrial appendage This stasis promotes intracardiac thrombus formation, which can dislodge and occlude cerebral or systemic vasculature despite episodes spontaneously resolving within seven days
- nih.gov
Clinical risk stratification guides prophylaxis, as the risk of thromboembolic events in paroxysmal disease remains comparable to that of sustained atrial fibrillation
- ccjm.org
Clinical risk stratification guides prophylaxis, as the risk of thromboembolic events in paroxysmal disease remains comparable to that of sustained atrial fibrillation
Personalize your experience
Follow Prevention of thromboembolism in paroxysmal atrial fibrillation and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.